Barrett's esophagus: Ordering the events that lead to cancer

European Journal of Cancer Prevention

Volumn 5, Issue SUPPL. 2, 1996, Pages 57-65

  Reid, B J ^a,b,c   Barrett, M T ^a   Galipeau, P C ^a   Sanchez, C A ^a   Neshat, K ^b   Cowan, D S ^a   Levine, D S ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CONFERENCE PAPER; ESOPHAGUS CARCINOMA; HUMAN; PRIORITY JOURNAL;

ANEUPLOIDY; BARRETT ESOPHAGUS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; GENES, P53; HUMANS; PRECANCEROUS CONDITIONS;

EID: 0030485631     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-199612002-00009     Document Type: Conference Paper

References (73)

1. Baker SJ, Preisinger AC, Jessup JM, et al. (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722.
2. Barrett MT, Reid BJ, Joslyn G (1995) Genotypic analysis of multiple loci in somatic cells by whole genome amplification. Nuc Acids Res 23:3368-3372.
3. Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ (1996a) Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell-sorting, whole genome amplification and microsatellite polymorphisms. Oncogene, 12:1873-1878.
4. Barrett MT, Sanchez CA, Galipeau PC, et al. (1996b) Mechanisms of neoplastic progression in Barrett's esophagus. In Pezcoller Foundation Symposium 1996, (in press).
5. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ (1996c) Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene, (in press).
6. Bennett Wp, Hollstein MC, Metcalf RA, et al. (1992) p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 52:6092-6097.
7. Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr. JF (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289.
8. Blount pL, Rabinovitch pS, Haggitt RC, Reid BJ (1990) Early Barrett's adenocarcinoma arises within a single aneuploid population. Gastroenterology 98:A273.
9. Blount PL, Ramel S, Raskind WH, et al. (1991) 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 51:5482-5486.
10. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ (1993) Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 90:3221-3225.
11. Blount PL, Galipeau PC, Sanchez CA, et al. (1994) 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 54:2292-2295.
12. Boynton RF, Blount PL, Yin J, et al. (1992) Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 89:3385-3388.
13. Boynton RF, Huang Y, Blount PL, et al. (1991) Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 51:5766-5769.
14. Carder P, Wyllie AH, Purdie CA, et al. (1993) Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8:1397-1401.
15. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA (1991) p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51:4495-4499.
16. Cross SM, Sanchez CA, Morgan CA, et al. (1995) p53-dependent mouse spindle checkpoint. Science 267:1353-1356.
17. 1 checkpoint control. Cell 82:675-684.
18. El-Deiry WS, Tokino T, Velculescu VE, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
19. Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal H (1989) Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 97:815-820.
20. Galipeau PC, Reid BJ (1995) The cell cycle, genomic instability, and clonal evolution in Barrett's esophagus. In Accomplishments in Cancer Research. Edited by JG Fortner and JE Rhoads. Philadelphia: JB Lippincott Co, 1994; pp 99-112.
21. 2/tetraploid) populations and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 93:7081-7084.
22. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN (1992) Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 103:1769-1776.
23. Hameeteman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG (1989) Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96:1249-1256.
24. Hamilton SR, Smith RRL, Cameron JL (1988) Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 19:942-948.
25. 1 cyclin-dependent kinases. Cell 75:805-816.
26. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327.
27. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-634.
28. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828.
29. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC (1978) Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 75:683-687.
30. Hereford LM, Hartwell LH (1974) Sequential gene function in the initiation of Saccharomyces cerevisiae DNA synthesis. Mol Biol 84:445-461.
31. Hirohashi S, Sugimura T (1991) Genetic alterations in human gastric cancer. Cancer Cells 3:49-52.
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53.
33. Huang Y, Boynton RF, Blount PL, et al. (1992) Loss of heterozygosity involves multiple tumor suppressor genes in hurnan esophageal cancers. Cancer Res 52:6525-6530.
34. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
35. Kastan MB, Zhan Q, El-Deiry WS, et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell 71:587-597.
36. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495.
37. Levine DS, Reid BJ (1992) Endoscopic diagnosis of esophageal neoplasms. In Gastrointestinal endoscopy clinics of North America. Edited by M Sivak, HW Boyce, GA Boyce. Philadelphia: W.B. Saunders; pp 395-413.
38. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ (1993) An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105:40-50.
39. Levine DS, Haggitt RC, Irvine S, Reid BJ (1996) Natural history of high-grade dysplasia in Barrett's esophagus [abstract]. Gastroenterology 110:550A.
40. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-936.
41. Lu X, Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765-778.
42. McKinley MJ, Budman DR, Grueneberg D, Bronzo RL, Weissman GS, Kahn E (1987) DNA content in Barrett's esophagus and esophageal malignancy. Am J Gastroenterology 82:1012-1015.
43. Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK. Cancer Statistics Review, 1973-1989. U.S. Department of Health and Human Services; NIH publication No 922789.
44. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H (1990) Surgical therapy of oesophageal carcinoma. Br J Surg 77:845-857.
45. Neshat K, Sanchez CA, Galipeau PC, et al. (1994) p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 106:1589-1595.
46. Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, Reid BJ (1995) Barrett's esophagus: a model of human neoplastic progression. In Symposium LIX: Molecular Genetics of Cancer. Cold Spring Harbor Symp on Quant Biol, LIX:577-583.
47. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23-28.
48. Offerhaus GJA, De Geyter EP, Cornelisse CJ, et al. (1992) The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 102:1612-1619.
49. Pellish LJ, Hermos JA, Eastwood GL (1980) Cell proliferation in three types of Barrett's epithelium. Gut 21:26-31.
50. Phillips RW, Wong RKH (1991) Barrett's esophagus: natural history, incidence, etiology and complications. Gastroenterol Clin North Am 20:791-816.
51. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE (1988) Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 60:65-71.
52. Ramel S, Reid BJ, Sanchez CA, et al. (1992) Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 102:1220-1228.
53. Raskind WH, Norwood T, Levine DS, Haggitt RC, Rabinovitch PS, Reid BJ (1992) Persistent clonal areas and clonal expansion in Barrett's esophagus. Cancer Res 52:2946-2950.
54. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS (1987) Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 93:1-11.
55. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, Van Deventer G, DenBesten L, Rubin CE (1988a) Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94:81-94.
56. Reid BJ, Haggitt RC, Rubin CE, et al. (1988b) Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19:166-178.
57. Reid BJ (1991) Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 20:817-834.
58. Reid BJ, Blount PL, Rubin CE, et al. (1992) Flow cytometric and histologic progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219.
59. Reid BJ, Sanchez CA, Blount PL, Levine DS (1993) Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105:119-129.
60. Robaszkiewicz M, Hardy E, Volant A, et al. (1991) Analyse du contenu cellulaire en ADN par cytometrie en flux dans les endobrachyoesophages. Gastroenterol Clin Biol 15:703-710.
61. Rusch VW, Levine DS, Haggitt R, Reid BJ (1994) The management of high-grade dysplasia and early cancer in Barrett's esophagus. Cancer 74:1225-1229.
62. Sandell LL, Zakian VA (1993) Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 75:729-739.
63. Schnell T, Sontag SJ, Chejfec G, et al. (1996) High-grade dysplasia is not an indication for surgery in patients with Barrett's esophagus [abstract]. Gastroenterology 110:590A.
64. Shackney SE, Smith CA, Miller BW, et al. (1989) Model for the genetic evolution of human solid tumors. Cancer Res 49:3344-3354.
65. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846-847.
66. Sozzi G, Miozzo M, Donghi R, et al. (1992) Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079-6082.
67. Spechler SJ (1987) Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice? Ann Int Med 106:902-904.
68. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK (1994) Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344:1533-1536.
69. Vogelstein B, Fearon ER, Hamilton SR, et al. (1988) Genetic alterations during colorectal tumor development. N Eng J Med 319:525-532.
70. Weinert TA, Hartwell LH (1988) The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322.
71. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature (Lond) 366:701-704.
72. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.
73. Younes M, Lebovitz RM, Lechago LV, Lechago J (1993) p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105:1637-1642.